The Court of Appeal today handed down its judgment dismissing the appeal of various pharmaceutical companies against an earlier judgment of the Competition Appeal Tribunal (“CAT”) finding that they had no limitation defence to a multi-million pound claim by English and Welsh NHS providers arising out of the “pay for delay” cartel in relation to citalopram, an important first-line treatment for depression routinely prescribed by GPs.
In 2013, the European Commission decided that Lundbeck, which held the original patent for citalopram, had breached EU competition law by agreeing with generic manufacturers that they would delay entry to the market for citalopram in return for being paid the equivalent of what they would have earned from earlier entry (hence, “pay for delay”). Those manufacturers had threatened to enter the market after the expiry of the main patent for citalopram, despite Lundbeck’s assertion that to do so would infringe some other patents held by Lundbeck in relation to the process of manufacturing citalopram (an assertion that the generic manufacturers denied).
Lundbeck and the generic manufacturers involved appealed against that decision to the General Court of the EU and then to the Court of Justice of the EU (“CJEU”). Their final appeals were dismissed by the Court of Justice on 25 March 2021.
Meanwhile, on the sixth anniversary of the decision, in 2019, the NHS and other providers started High Court proceedings for damages against the companies involved. In 2021, but before any Particulars of Claim had been pleaded, those proceedings were transferred to the CAT: the order made provision for a Claim Form to be served in accordance with CAT rules in lieu of Particulars of Claim. The NHS served that Claim Form on 28 February 2023, and an amended version adding a further party (“the 12th Defendant”) on 17 March 2023. The Claim Form was entirely a “follow-on” claim relying only on the infringement found in the Commission decision.
It was common ground that: –
- the High Court proceedings were served out of time: the Defendants alleged, and the NHS did not dispute, that the six-year period ran from before the publication of the Commission decision given the material available to the NHS before publication; and
- on the basis of the limitation periods applicable to pre-2015 follow-on claims and preserved by transitional provisions in the CAT Rules, there was a separate limitation period for follow-on claims in the CAT of two years running from the date of the CJEU’s judgment.
On that basis, the issue between the NHS and the Defendants was whether the Claim Form served in February and March 2023 – within two years of the CJEU judgment – validly made a follow-on claim. The Defendants said it did not, and should only be regarded as a step in the transferred High Court proceedings (which were out of time). They also claimed that the NHS was estopped by the terms of the transfer order – which preserved the parties “accrued rights” – from relying on the two-year limitation period.
Green LJ, giving a judgment with which Flaux C and Phillips LJ agreed, upheld the CAT in rejecting the Defendants’ limitation defence. He pointed out that the Defendants’ case was, in the end, that the NHS should have withdrawn the transferred proceedings before serving the Claim Form. But there was no reason why, even though the NHS had not done that, the Claim Form should not have the effect under rule 30 of the CAT rules of “making” a claim: Green LJ stated that (§62): –
The [Defendants’] case … proceeds upon the basis that an ostensibly regular claim is irregular because of a procedural omission which is external to and uncontemplated by the Rules. That omission is the failure to take a wholly unnecessary procedural step, namely the abandonment of a prior High Court claim. The Appellants’ interpretation of [the relevant rules] collide, in my view violently, with the General Principles of fairness, justice and proportionality, which guide the construction and operation of the Rules.
Green LJ then rejected the Defendants’ estoppel argument on the basis that there was no reason to read the reference to preservation of “accrued rights” as including an agreement by the NHS to give up a right to rely on the two-year period (which had at that stage not yet commenced). In any event, that argument could not assist the 12th Defendant, which was not party to the transfer order on which the alleged estoppel was based.
Subject to any application by the Defendants to appeal to the Supreme Court, the NHS’s claim for damages will now proceed in the CAT.
George Peretz KC (instructed by Peters & Peters Solicitors LLP) represented the NHS in the CAT (as from 2024) and the Court of Appeal. He also represented the European Commission in the General Court and CJEU appeals against its 2013 decision.